Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors

Advanced Solid Tumor Clinical Trial

— IMMINENT-01  

Official title:

A Phase 1/2a Open-Label, Dose-Escalation/Dose-Expansion Safety, Tolerability and Anti-tumor Activity Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05840835
• Other study ID #: IMX-110-002
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: February 3, 2023
• Est. completion date: January 24, 2024

Study information

• Verified date: August 2023
• Source: Immix Biopharma, Inc.
• Contact: Ilya Rachman, MD
• Phone: 8889581084
• Email: info[@]immixbio.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Phase 1/2a Phase 1 is an open-label, multicenter dose escalation/dose expansion study designed to assess the safety, tolerability, pharmacokinetics (PK) and antitumor activity of IMX-110 in combination with Tislelizumab. The recommended Phase 2 dose (RP2D) will be evaluated in further dose expansion Phase 2a study submitted as an amendment to this Phase 1 protocol during the conduct of the Phase 1 study.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: January 24, 2024
• Est. primary completion date: January 24, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 16 Years and older

Eligibility

Inclusion Criteria:

• Male or female patients who are 16 years or older
• Patients with confirmed advanced solid tumor as per histology, who have progressed, are refractory, or are intolerant to standard therapy appropriate for tumor type
• Patients with an Eastern Cooperative Oncology Group (ECOG) Performance status of 0-2 (Appendix 2)
• Patients with a life expectancy of at least 3 months
• Patients with adequate cardiac function as measured by left ventricular ejection fraction >50%
• Patients who have not reached a cumulative total lifetime maximum dose of 550 mg/m2 doxorubicin or per investigator discretion
• Patients who meet the following laboratory requirements:
• Absolute neutrophil count (ANC) = 1.0 x 109/L
• Hemoglobin (HGB) = 9.0 g/dL (patients may be transfused to achieve this HGB level)
• Platelet count = 100 x 109/L
• Total bilirubin level = 1.5 x ULN, or = 3.0 x ULN for patients with Gilbert syndrome
• AST and ALT = 2.5 x ULN (=5 x ULN if liver metastasis present)
• Creatinine = 1.5 x ULN (Creatinine clearance >50 mL/min/1.73 m2 for subjects with creatinine levels above institutional normal) (Creatinine clearance will be measured based on Cockcroft-Gault Equation).
• Women of childbearing potential and men must agree to sexual abstinence or to use highly effective, double barrier contraception during the study and for 6 weeks following the final dose of IMX-110. Double barrier contraception is defined as a

condom AND one other form of the following:

• Birth control pills (The Pill)
• Depot or injectable birth control
• IUD (Intrauterine Device)
• Birth control patch (e.g. Ortho Evra)
• NuvaRing®
• Documented evidence of surgical sterilization at least 6 months prior to the screening visit, i.e., tubal ligation or hysterectomy for women or vasectomy for men. Male patients must not donate sperm for at least 24 weeks post-dose of the last study treatment. Females of childbearing potential must have a negative serum pregnancy test at Screening and a negative urine pregnancy test on Day -1. Rhythm methods during the study and for 4 months after the dose of IMX-110 + Tislelizumab will not be acceptable.

Exclusion Criteria:

• Patients with a history of severe allergic reactions to any unknown allergens or any components of the study drug formulation.
• Patients receiving any chemotherapy within 14 days of dosing, immunotherapy within 28 days of dosing, or biologic or hormonal therapy within 28 days of dosing for cancer treatment (exclusively). Patients with prostate cancer can continue administration of Gonadotropin-releasing hormone (GnRH) agonists.
• Subject participating in any other drug study = 4 weeks (6 weeks for immunotherapy investigational agents) or 5 half-lives of the investigational product, whichever is longer, prior to study drug administration or is scheduled to receive one during the treatment or post-treatment period.
• Patients who are expected to need surgery or benefit from other anti-cancer therapy to be initiated during the study period.
• Patients with a history of and/or risk factors for ischemic heart disease, congestive heart failure, symptomatic bradycardia, atrioventricular (AV) block of second degree or higher grade, prolonged QTcF interval (>450 msec in men and >470 msec in women and additional risk factors for QT prolongation (e.g. hyperthyroidism, electrolyte imbalance). (Pacemaker is not prohibited).
• Patients who have not recovered from adverse events (AEs; = CTCAE grade 2) due to prior treatment (i.e. chemotherapy, targeted therapy, radiation, or surgery) within 7 days prior to Cycle 1 Day 1, unless deemed to be irreversible, or approved by the Sponsor and Medical Monitor.
• Females who are pregnant or lactating or intend to become pregnant before, during, or within 24 weeks after participating in this study; or intending to donate ova during such time period.
• Patients with a known positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C antibodies (HCV). Patients may be enrolled if they have HBV, HCVor HIV with viral load suppressed by anti-virals. Any condition that, in the opinion of the investigator or sponsor, would interfere with evaluation of the investigational product.
• Active autoimmune diseases or history of autoimmune diseases that may relapse or history of life-threatening toxicity related to prior immune therapy. Note: Patients

with the following diseases are not excluded and may proceed to further screening:

• Controlled type I diabetes (insulin dependent)
• Hypothyroidism (provided it is managed with hormone replacement therapy only)
• Controlled celiac disease
• Skin diseases not requiring systemic treatment (eg, vitiligo, psoriasis, alopecia)
• Any other disease that is not expected to recur in the absence of external triggering factors (requires consultation with the medical monitor prior to enrollment)
• Indicated live vaccines should be given =4 weeks prior to enrollment

Related Conditions & MeSH terms

• Advanced Solid Tumor
• Neoplasms

Intervention

Drug:
• IMX-110 combined with Tislelizumab
Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors

Locations

Country	Name	City	State
Brazil	CIP Centro Integrado de Pesquisa / Hospital de Base / Fundação Faculdade de Medicina de São José do Rio Preto	São José do Rio Preto	São Paulo
Brazil	Instituto do Cancer do Estado de São Paulo (ICESP)	São Paulo	Sao Paulo

Sponsors (3)

Lead Sponsor	Collaborator
Immix Biopharma, Inc.	BeiGene, Novartis

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v5.0	Incidence, severity and causality of AE and serious adverse events (SAE) / Physical examination changes from baseline / Vital sign changes from baseline (heart rate, systolic/diastolic blood pressure, respiratory rate, and temperature) / Hematology and chemistry parameter changes from baseline / 12-lead ECG and 2-D Echocardiogram changes from baseline	28 days
Primary	Maximum tolerated doses (MTDs) and RP2D of IMX-110 in combination with Tislelizumab	MTD is defined as the highest dose at which = 33% of the patients treated during the 3+3 design experience a DLT and/or at least two = grade 2 non-hematologic toxicities during the first treatment cycle, and will be used to identify the RP2D to be taken forward to Phase 2a.	28 days
Secondary	Plasma concentrations of IMX-110	Plasma concentration of IMX-110 will be measured when administered in treatment Cycle 1. Samples will be collected on Day 1 (pre-dose, and immediately after, 5 minutes, 1 hour, 1.5 hours, 3 hours, 5 hours post-dose), on Day 2 (pre-dose), and Day 5 (pre-dose and immediately after, 5 minutes, 1 hour, 1.5 hours, 3 hours, 5 hours post-dose), and optionally on Day 7 (pre-dose, 5 minutes, 15 minutes, 1 hour, 1.5 hours, 3 hours, 5 hours post-dose).	7 days
Secondary	Response Rate	Objective Response Rate as determined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1 and iRECIST	8 weeks
Secondary	Progression-free survival (PFS)	PFS is measured from the start of treatment to the time of progression or death, whichever occurs first while on the study.	5 years
Secondary	Overall Survival (OS)	OS is defined as the time from Cycle 1 Day1 to death due to any cause.	5 years
Secondary	Duration of Response (DOR)	DOR as determined by RECIST criteria version 1.1 and iRECIST	5 years